Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-26 @ 11:07 AM
Ignite Modification Date: 2025-12-26 @ 11:07 AM
NCT ID: NCT04872712
Eligibility Criteria: Inclusion Criteria: * Health care workers treating COVID-19 patients in Cipto Mangunkusumo Hospital. * Has Symptoms of insomnia for at least 2 weeks (screened using the PHQ-9 instrument modified to question number 3a with an answer score of at least 1) * Age 20 - 50 years. * Has negative COVID-19 rapid test or PCR swab result in the 7 days prior to the study. * Willing to participate in research by signing an informed consent. * Willing to follow the research process to completion. Exclusion Criteria: * If you answered Yes to PHQ-9 number 3a never or 3b with a yes * Insomnia is caused by moderate pain (with Numeric Rating Scale \> 4) * Insomnia patients with medical therapy such as benzodiazepines, non-benzodiazepines, melatonin drugs and antidepressants * Has severe social and occupational dysfunction (with the Global Assessment of Functioning \< 50). * Has a history of contraindications to acupuncture such as medical emergencies, pregnancy, thrombocytopenia with a platelet count below 50,000 per microliter of blood, history of blood clotting disorders / taking blood thinners, puncturing over malignant tumors, or infection or scarring in the acupuncture area. * The patient is febrile with a temperature more than 38 Celsius * Have had acupuncture in the last 7 days prior to study. * No limbs * Cognitive impairments or impaired consciousness
Healthy Volunteers: False
Sex: ALL
Minimum Age: 20 Years
Maximum Age: 50 Years
Study: NCT04872712
Study Brief:
Protocol Section: NCT04872712